Table 2.
Outcomes after allogeneic hematopoietic stem cell transplant in patients with therapy related ALL
| Study | t-ALL (N) | Most frequent cytogenetic abnormality | Allo HSCT n (%) | NRM | Outcomes after Allo HSCT (2-year OS) |
|---|---|---|---|---|---|
| Shivakumar et al. [44] | 89b | 11q23 rearrangement | 14 (15.73) | NA | NA |
| Abdulwahab et al. [5] | 23 | 11q23 rearrangement | 5 (21.7) | 20% (2 years) | 60% |
| Ganzel et al. [34] | 23 | t (9; 22) | 8 (34.8)a | NA | NA |
| Kelleher et al. [45] | 16 | Hyperdiploidy (33%) | 2 (12.5) | NA | NA |
| Aldoss et al. [39] | 93 | t (9; 22) | 49 (53.7) | 28.5% (unknown time) | 53.4% |
| Saygin et al. [10] | 116 | t (9; 22) | 42 (36.2) | NA | NA (median OS 46 months) |
| Vasudevan et al. [42] | 18 | 11q23 rearrangement | 18 (100) | 33.3% (2 years) | 51.8% |
t-ALL therapy related acute lymphoblastic leukemia, Allo HSCT allogeneic hematopoietic stem cell transplant, NRM non relapse mortality, OS overall survival, NA not available
aBoth secondary ALL(s-ALL) and t-ALL combined
bIncludes both own patients and that collected from literature